Abcam’s €120 Million Acquisition Of Expedeon AG’s Proteomics And Immunology Business


Herbert Smith Freehills is advising Abcam on its acquisition of Expedeon AG’s proteomics and immunology business.

The transaction values the business to be acquired at €120 million, is subject to approval by Expedeon AG’s shareholders and is expected to close in early 2020. The acquisition includes leading protein conjugation technologies and brands including Lightning-Link® and CaptSureTM, and will provide Abcam’s existing business with access to the complementary antibody conjugation and labelling market.

Alan Montgomery (Picture), M&A Partner in London and co-Head of HSF’s global Pharmaceuticals practice, led the team advising Abcam, assisted by senior associate Lerryn Martin and associate Stuairt Tosh. German law input was provided by Nico Abel (partner) and Julius Brandt (senior associate) in HSF’s Frankfurt office, whilst specialist support was provided by Joel Smith (partner), Andrew Wells (senior associate), Peter Dalton (senior associate) and Monika Klajn (associate) in HSF’s intellectual property team and Isaac Zailer (partner) and David Alexander (associate) in HSF’s tax team.

Involved fees earner: Nico Abel – Herbert Smith Freehills; David Alexander – Herbert Smith Freehills; Julius Brandt – Herbert Smith Freehills; Peter Dalton – Herbert Smith Freehills; Monika Klajn – Herbert Smith Freehills; Lerryn Martin – Herbert Smith Freehills; Alan Montgomery – Herbert Smith Freehills; Joel Smith – Herbert Smith Freehills; Stuairt Tosh – Herbert Smith Freehills; Andrew Wells – Herbert Smith Freehills; Isaac Zailer – Herbert Smith Freehills;

Law Firms: Herbert Smith Freehills;

Clients: Abcam PLC;